T-Cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to Overlapping Epitopes Containing Multiple HLA-I and -II Binding Motifs

PLoS Neglected Tropical Diseases

Volumn 7, Issue 1, 2013, Pages

  de Melo, Andréa Barbosa ^a   Nascimento, Eduardo J M ^b   Braga Neto, Ulisses ^c   Dhalia, Rafael ^a   Silva, Ana Maria ^a   Oelke, Mathias ^d   Schneck, Jonathan P ^d   Sidney, John ^e   Sette, Alessandro ^e   Montenegro, Silvia M L ^a   Marques, Ernesto T A ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Texas AandM University   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYTOKINE; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ARTICLE; BINDING ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; YELLOW FEVER;

EID: 84873507049     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001938     Document Type: Article

References (43)

1. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900.
2. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
3. Monath TP, (2005) Yellow fever vaccine. Expert Rev Vaccines 4: 553-574.
4. Barrett AD, Teuwen DE, (2009) Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21: 308-313.
5. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, (1998) Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159-167.
6. Pulendran B, (2009) Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9: 741-747.
7. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865-4873.
8. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, et al. (2010) CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185: 5405-5416.
9. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
10. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
11. Co MD, Kilpatrick ED, Rothman AL, (2009) Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 128: e718-727.
12. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL, (2002) Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293: 151-163.
13. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, et al. (2008) Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712-5721.
14. de Melo AB, da Silva Mda P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, et al. (2011) Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739-747.
15. Roederer M, Koup RA, (2003) Optimized determination of T cell epitope responses. J Immunol Methods 274: 221-228.
16. Oelke M, Krueger C, Giuntoli RL 2nd, Schneck JP, (2005) Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med 11: 412-420.
17. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, et al. (2003) Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9: 619-624.
18. Oelke M, Schneck JP, (2004) HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol 110: 243-251.
19. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, et al. (2011) Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63: 325-335.
20. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, et al. (2008) Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 4: 2.
21. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, et al. (2001) Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol Chapter 18: Unit 18, 13.
22. Sidney J, Steen A, Moore C, Ngo S, Chung J, et al. (2010a) Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. J Immunol 185: 4189-4198.
23. Sidney J, Steen A, Moore C, Ngo S, Chung J, et al. (2010b) Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol 184: 2492-2503.
24. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, et al. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183: 7919-7930.
25. Wang B, Norbury CC, Greenwood R, Bennink JR, Yewdell JW, et al. (2001) Multiple paths for activation of naive CD8+ T cells: CD4-independent help. J Immunol 167: 1283-1289.
26. Gerloni M, Xiong S, Mukerjee S, Schoenberger SP, Croft M, et al. (2000) Functional cooperation between T helper cell determinants. Proc Natl Acad Sci U S A 97: 13269-13274.
27. Gerloni M, Castiglioni P, Zanetti M, (2005) The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol 175: 6551-6559.
28. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160: 3363-3373.
29. Maciel M Jr, Kellathur SN, Chikhlikar P, Dhalia R, Sidney J, et al. (2008) Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 378: 105-117.
30. Lund O, Nascimento EJ, Maciel M Jr, Nielsen M, Larsen MV, et al. (2011) Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One 6: e26494.
31. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17: 555-561.
32. Kobayashi H, Lu J, Celis E, (2001) Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61: 7577-7584.
33. Panigada M, Sturniolo T, Besozzi G, Boccieri MG, Sinigaglia F, et al. (2002) Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infect Immun 70: 79-85.
34. Matloubian M, Concepcion RJ, Ahmed R, (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056-8063.
35. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188: 2205-2213.
36. Bevan MJ, (2004) Helping the CD8(+) T-cell response. Nat Rev Immunol 4: 595-602.
37. Wilson DB, Wilson DH, Schroder K, Pinilla C, Blondelle S, et al. (2004) Specificity and degeneracy of T cells. Mol Immunol 40: 1047-1055.
38. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, et al. (2010) A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 5: e11072.
39. O'Sullivan D, Arrhenius T, Sidney J, Del Guercio MF, Albertson M, et al. (1991) On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol 147: 2663-2669.
40. Hammer J, Valsasnini P, Tolba K, Bolin D, Higelin J, et al. (1993) Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197-203.
41. Kilgus J, Jardetzky T, Gorga JC, Trzeciak A, Gillessen D, et al. (1991) Analysis of the permissive association of a malaria T cell epitope with DR molecules. J Immunol 146: 307-315.
42. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237-2242.
43. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, et al. (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178: 27-47.